Hormonal
Unsaturated fatty acids, particularly omega-3 PUFAs like linoleic, oleic, and docosahexaenoic acid, stimulate insulin and glucagon secretion via activation of FFAR1 and FFAR4, improving glucose tolerance.
Incorporate unsaturated fatty acids, especially omega-3 PUFAs found in fish, nuts, and seeds, into your diet. These fatty acids activate FFAR1 and FFAR4 receptors, which can stimulate the release of insulin and glucagon, helping to regulate blood sugar levels. This is particularly beneficial for individuals with insulin resistance or type 2 diabetes.
Taken together, available evidence shows that unsaturated fatty acids, and especially omega-3 PUFAs influence glucose homeostasis by serving as potent ligands for FFAR1 and FFAR4 expressed by pancreatic islets and enteroendocrine cells.
Why this rating
Supported by in vitro and in vivo studies using specific fatty acids and knockout models.
Source
GPCR-mediated effects of fatty acids and bile acids on glucose homeostasis
Antwi‐Boasiako Oteng et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2023.1206063
More from this paper
- Short-chain fatty acids (SCFAs) such as acetate and propionate regulate glucose homeostasis primarily by activating the GPCR FFAR2 on enteroendocrine L-cells, stimulating the release of GLP-1, which in turn promotes insulin secretion and improves glucose tolerance.Good
- Bile acids, particularly lithocholic acid and hyocholic acid, improve glucose tolerance by activating the GPCR GPBAR1 (TGR5) on enteroendocrine cells, leading to increased GLP-1 secretion and insulin release.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →